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Abstract
 
An effective type I interferon (IFN-
 
 
 
/
 
 
 
) response is critical for the control of many viral infec-
tions. Here we show that in vesicular stomatitis virus (VSV)-infected mouse embryonic fibro-
blasts (MEFs) the production of IFN-
 
 
 
 is dependent on type I IFN receptor (IFNAR) triggering,
whereas in infected mice early IFN-
 
 
 
 production is IFNAR independent. In VSV-infected
mice type I IFN is produced by few cells located in the marginal zone of the spleen. Unlike
other dendritic cell (DC) subsets, FACS
 
®
 
-sorted CD11c
 
int
 
CD11b
 
 
 
GR-1
 
 
 
 DCs show high
IFN-
 
 
 
 expression, irrespective of whether they were isolated from VSV-infected IFNAR-
competent or -deficient mice. Thus, VSV preferentially activates a specialized DC subset pre-
sumably located in the marginal zone to produce high-level IFN-
 
 
 
 largely independent of
IFNAR feedback signaling.
Key words: IFN type I • virus infection • dendritic cell subsets • IFN regulatory factor 7 • 
type I IFN receptor
 
Introduction
 
Type I IFNs (IFN-
 
 
 
/
 
 
 
) constitute a family of cytokines
comprising in the mouse at least 11 IFN-
 
 
 
 isoforms and
one IFN-
 
 
 
, which were identified by their ability to pro-
tect cells against viral infection (1). For a broad spectrum of
viruses a functional type I IFN response is critical for the
survival of the infected host (2, 3). Beyond the direct an-
tipathogenic activity, type I IFNs synergize with other
proinflammatory stimuli to activate innate effectors such as
NK cells, macrophages, and dendritic cells (DCs)
 
*
 
 (4)
and may modulate antigen presentation and the adaptive
immune response (5).
The biologic activity of all IFN-
 
 
 
 subtypes and of IFN-
 
 
 
 is
mediated by binding to the common type I IFN recep-
tor (IFNAR), a heterodimer consisting of the 
 
 
 
-chain
(IFNAR-1) and the 
 
 
 
-chain (IFNAR-2, references 6 and
7). IFNAR signaling activates a multitude of IFN-inducible
genes whose products may drastically alter cell homeostasis;
in order to impede viral replication, cell proliferation is
halted and both transcription and translation are strongly
reduced. High-level expression of type I IFN, that can be
detrimental to the host (8, 9), is tightly regulated (10) and
usually restricted to the state of acute viremia.
The molecular mechanism of type I IFN induction
was intensively investigated by analyzing virus-stimulated
mouse embryonic fibroblasts (MEFs) derived from gene-
targeted mice deficient of factors involved in the type I
IFN signaling cascade. MEFs from mice lacking IFN-
 
 
 
,
IFNAR-1, signal transducer and activator of transcription
1, or IFN regulatory factor (IRF)-9 showed a defective
IFN-
 
 
 
 response (11–14). This suggested that after the pro-
duction of early IFN-
 
 
 
, and possibly IFN-
 
 
 
4, expression
of other IFN-
 
 
 
 genes was dependent on IFNAR feedback
signaling. Two members of the IRF family, IRF-3 and
IRF-7, have been shown to play a key role in the sequen-
tial induction of type I IFN genes. Virus-mediated serine
phosphorylation leads to IRF-3 activation and translocation
to the nucleus (15). There, IRF-3 is part of an enhanceo-
some complex promoting the expression of IFN-
 
 
 
, and
presumably of IFN-
 
 
 
4. Early type I IFN is secreted and
triggers IFNAR signaling in an autocrine fashion. Among
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other type I IFN–induced genes, IFNAR signaling strongly
upregulates IRF-7 expression (12, 13). Virus infection leads
to IRF-7 activation by phosphorylation that drives the ex-
pression of the majority of IFN-
 
 
 
 subtypes, and hence am-
plifies the type I IFN response. It is not known, however,
which serine kinase(s) is/are responsible for the activation
of IRF-3 and IRF-7. It appears that several pathways may
lead to IRF-3 and IRF-7 activation. Some viruses, such as
type I herpes simplex virus (HSV), induce an IFN response
independent of viral replication whereas others, e.g., vesic-
ular stomatitis virus (VSV), lose the ability to induce type I
IFN upon inactivation. Furthermore, a variety of nonviral
IFN inducers has been described, including prokaryotic
DNA motifs (CpG-DNA), synthetic double-stranded RNA
(poly[I:C]), lipopolysaccharide, and imiquimod derivatives
(16, 17).
In cell culture, virtually any cell type can produce type I
IFN in response to appropriate stimulation, yet, depending
on the expression of pattern recognition receptors distinct
cell types are stimulated by different IFN inducers. For
example CpG-DNA but not poly(I:C)–treated human
CD11c
 
 
 
 DCs produce type I IFN, whereas a reverse cor-
relation was found for CD11c
 
 
 
 DCs (17, 18). Accord-
ingly, CD11c
 
 
 
 DCs express the Toll-like receptor (TLR)-9
and CD11c
 
 
 
 DCs express TLR-3 (17, 19), which have
been shown to be involved in the recognition of CpG or
poly(I:C), respectively (20, 21). So far, the major IFN-
producing cell (IPC) has not been defined in the context
of infection with specific pathogens. Several studies ad-
dressed the nature of the human IPC (22–24), which
eventually was defined as the subset of CD11c
 
 
 
 plasmacy-
toid DCs (25, 26). There are indications that upon stimu-
lation of mice certain macrophages (27) or DC subsets can
produce type I IFN (28–30).
Considering the above information, in an acutely in-
fected host fibroblasts presumably do not produce the ma-
jority of type I IFN. Therefore, we investigated whether
the positive feedback regulation of type I IFN induction, as
identified in MEFs, also plays a role in viral pathogenesis
in vivo. Surprisingly, VSV- and UV-HSV–treated mice
mount early IFN-
 
 
 
 responses largely independent of
IFNAR feedback signaling. We provide evidence that un-
like fibroblasts, mouse IPCs can produce early IFN-
 
 
 
 inde-
pendent of IFNAR signaling. These data are discussed in
the context of an extended model of IFN-
 
 
 
 induction
based on the cell type involved in the production of IFN-
 
 
 
.
 
Materials and Methods
 
Mice and Viruses.
 
IFNAR-deficient mice (IFNAR
 
 
 
/
 
 
 
) on the
SV129 background (3) and IFN-
 
 
 
 
 
/
 
 
 
 
 
mice on the Balb/c back-
ground (14) were bred under specific pathogen free (SPF) condi-
tions. Unmutated SV129 mice (referred to as wild-type [WT])
were obtained from the SPF-breeding colony of the European
Mutant Mouse Archive (EMMA), Monterotondo, Italy. C57BL/6
mice were purchased at IFFA-Credo. Experimental mouse
work was done under SPF conditions in compliance with regula-
tions of the Ministerio della Sanità, Rome, Italy (decreto ministe-
riale n
 
 
 
 15/2001-b, 3/3.1). VSV-IND (Mudd-Summers isolate)
was originally obtained from D. Kolakofsky, University of
Geneva, Geneva, Switzerland. VSV was grown on BHK-21 cells
(31) and plaqued on Vero cells. Stocks were maintained in MEM
containing 2% heat-inactivated FCS. HSV strain F originally ob-
tained by American Type Culture Collection was grown on Vero
cells. HSV was purified from cell culture supernatant by PEG
40.000 (Serva) precipitation. After several pelleting steps for 1 h at
43,000 
 
g
 
 virus was resuspended in PBS and titrated on Vero cells.
After UV irradiation (1.2 Joule/cm
 
2
 
) HSV inactivation was veri-
fied by plaquing on Vero cells.
 
Cell Culture.
 
WT and IFNAR
 
 
 
/
 
 
 
 MEFs were derived from
day 13 embryos (32) and maintained in DMEM supplemented
with 10% FCS. Cell monolayers were infected with VSV at a
multiplicity of infection (MOI) of 10. After 1 h of incubation at
37
 
 
 
C the virus suspension was replaced by DMEM 10% FCS.
 
Expression Analysis.
 
Preparation of total RNA was performed
using the TRIZOL reagent (GIBCO BRL) according to the
manufacturer’s instructions. Tissue samples were snap-frozen and
homogenized in Trizol using a Polytron (Kinematica). On cul-
tured cell monolayers and FACS
 
®
 
-sorted cells Trizol was applied
directly. To eliminate possible DNA contamination total RNA
was incubated for 15 min at 37
 
 
 
C with 10 U of DNase (Boeh-
ringer Mannheim). cDNA was prepared using Superscript II
(GIBCO BRL) according to the manufacturer’s instructions. To
estimate relative amounts of specific mRNAs, PCRs were per-
formed with serially fivefold diluted cDNA using published
primers for IFN-
 
 
 
 (consensus primers annealing with all IFN-
 
 
 
subtypes) and IRF-7 (13). The mRNA content was normalized
by RT-PCR analysis with GAPDH-specific primers from the
same publication. The absence of contaminating DNA was veri-
fied by PCR analysis of RNA preparations not treated with re-
verse transcriptase.
 
Quantification of IFN Activity.
 
The IFN bioassay was based on
the protection of L929 cells from the cytopathic effect (CPE) of
VSV (CPE inhibition assay). To inactivate potential viral con-
tamination, 1:5 prediluted serum samples from VSV-infected
mice were UV-irradiated with 1.2 Joule/cm
 
2
 
. Duplicates of seri-
ally twofold diluted sera were transferred to 24 h preincubated
semiconfluent monolayers of L929 cells in 96-well plates. After
24 h incubation at 37
 
 
 
C supernatants were removed and VSV
was added at a MOI of 0.05. After 48 h incubation at 37
 
 
 
C, su-
pernatants were taken away and protected cells were stained with
0.5% crystal violet in 5% formaldehyde, 50% ethanol, and 0.8%
sodium chloride. After extensive washing with water and air dry-
ing, the dye was extracted from stained cells with 100 
 
 
 
l/well 0.1 M
sodium citrate in 50% ethanol, pH 4.2, and the crystal violet
content was determined on an ELISA reader at 570 nm. In the
CPE inhibition assay an international mouse IFN-
 
 
 
/
 
 
 
 reference
standard of 100 IU/ml (Gu02–901–511; NIAID Repository) and
recombinant IFN-
 
 
 
A standards (PBL Biomedical Laboratories) of
100, 500, 2,500, and 10,000 IU/ml were included. For IFN
quantification the 50% protective serum dilution was indicative.
A log
 
2
 
5 titer corresponded to 1,000 IU IFN-
 
 
 
A. The contribu-
tion of IFN-
 
 
 
 or IFN-
 
 
 
 to the total type I IFN activity was de-
termined by preincubating sera for 1 h with excess amounts of
neutralizing anti–IFN-
 
 
 
 (clone 4E-A1; Yamasa Shoyu) or anti-
IFN-
 
 
 
 (clone 7F-D3; Yamasa Shoyu) mAbs. Protection from
CPE due to IFN-
 
 
 
 was formally excluded by an IFN-
 
 
 
 Elisa
(Promega) indicating that the IFN-
 
 
 
 content of all samples tested
was below the detection threshold of the assay.
 
Immunohistochemistry.
 
Freshly removed organs were im-
mersed in HBSS and snapped frozen in liquid nitrogen. Tissue 
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sections of 5-
 
 
 
m thickness were cut in a cryostat, placed on sili-
conized glass slides, air dried, fixed with acetone for 10 min, and
stored at –70
 
 
 
C. IFN was stained using a polyclonal sheep anti–
mouse IFN-
 
 
 
/
 
 
 
 antiserum (PBL Biomedical Labs) or mono-
clonal rat anti–mouse IFN-
 
 
 
 antibody (Serotec). The primary
sheep antibody was detected with affinity purified biotinylated
donkey anti–sheep Ig antibodies (Jackson ImmunoResearch Lab-
oratories) and alkaline phosphatase labeled avidin/biotin com-
plexes (ABC/AP Dako). The primary rat mAb was detected with
affinity purified peroxidase labeled goat anti–rat Ig antibody. For
signal amplification by catalyzed reporter deposition, biotinylated
thyramine (33) and 3% H
 
2
 
O
 
2
 
 was added for 7 min, and covalently
bound biotin was revealed by ABC/AP. Alkaline phosphatase
was visualized using naphthol AS-BI (6-bromo-2-hydroxy-3-
naphtholic acid-2-methoxy anilide) phosphate and new fuchsin as
substrate. Endogenous alkaline phosphatase was blocked by le-
vamisole. The dilutions of secondary antibodies were made in
TBS containing 5% normal mouse serum. Incubations were done
at room temperature for 30 min; TBS was used for all washing
steps. Color reactions were performed at room temperature for
15 min with reagents from Sigma-Aldrich. Sections were coun-
terstained with hemalum and coverslips mounted with glycerol
and gelatin.
 
In Situ Hybridization of IRF-7 mRNA.
 
Spleens were fixed
overnight in 4% paraformaldehyde in PBS and then embedded in
paraffin wax. Sections were cut at 5–7-
 
 
 
m and mounted onto
Superfrost-Plus slides (BDH). The IRF-7 riboprobe was gener-
ated by cloning a 351 bp RT-PCR product into pBluescript fol-
lowed by Digoxygenin-11-UTP-labeling using the Boehringer
RNA labeling kit. In situ hybridization was performed as de-
scribed previously (34).
 
DC Subset Isolation by FACS
 
®
 
 Sorting.
 
Single cell suspension
of 3–5 spleens was prepared and CD11c
 
 
 
 cells were enriched by
magnetic adsorption cell sorting (MACS
 
®
 
; Miltenyi Biotec).
Three-color stainings were made using anti-CD11c–biotin–,
anti-CD11b–FITC–, and anti-GR-1–PE–conjugated mAbs fol-
lowed by streptavidin-APC (all from BD PharMingen). 4–10
 
  
 
10
 
4
 
 cells of each subset were sorted from 
 
 
 
10
 
7
 
 cells on a MoFlo
cytometer (Cytomation).
 
Results
 
Feedback Signaling Is Required for the Expression of IFN-
 
 
 
mRNA in VSV-infected MEFs but not in VSV-infected
Mice.
 
Tissue culture experiments have shown previously
that the expression of all IFN-
 
 
 
 genes, except IFN-
 
 
 
4, was
dependent on IFNAR feedback signaling in Newcastle dis-
ease virus (NDV)-stimulated MEFs (12, 13). To validate
this finding under conditions of a productive virus infec-
tion, IFNAR competent (WT) and IFNAR-deficient
(IFNAR
 
 
 
/
 
 
 
) MEFs were VSV-infected and IFN-
 
 
 
 mRNA
expression was monitored by RT-PCR analysis. WT fi-
broblasts showed elevated IFN-
 
 
 
 mRNA levels beginning
4 h after VSV infection and peak expression between 9 h
and 12 h (Fig. 1 a). Similar to NDV-stimulated MEFs,
VSV-infected MEFs predominantly expressed IFN-
 
 
 
4 as
determined by subcloning of RT-PCR products and se-
quence analysis of random clones (Fig. 2 a). In contrast,
IFN-
 
 
 
 upregulation was not observed in VSV-infected
MEFs lacking the IFNAR (Fig. 1 a). Thus, in VSV-
infected MEFs the IFN-
 
  
 
production is strictly dependent
on IFNAR feedback signaling.
To next examine IFN responses in vivo, IFN-
 
 
 
 gene
expression was analyzed in spleen from WT and IFNAR
 
 
 
/
 
 
 
mice infected with VSV. Surprisingly, IFN-
 
 
 
 mRNA was
induced rapidly and to a similar extent in spleen of WT and
IFNAR
 
 
 
/
 
 
 
 
 
mice. At later time points, IFN-
 
 
 
 expression in
spleen of IFNAR
 
 
 
/
 
 
 
 
 
mice decreased slightly, whereas
spleen from WT mice showed a further increase in IFN-
 
 
 
expression (Fig. 1 b). The IFN-
 
 
 
 subtype analysis revealed
that both VSV-infected IFNAR-competent and -deficient
Figure 1. VSV infection stim-
ulates IFNAR-independent pro-
duction of IFN-  in mice, but
not in MEFs. (a) MEFs derived
from WT or IFNAR-deficient
mice (IFNAR / ) were in-
fected with VSV at a MOI of 10
and (b) WT and IFNAR / 
mice were intravenously injected
with 2   108 PFU VSV. Total
RNA of 106 cultured MEFs or
of spleen tissue was extracted, and
the mRNA content of different
samples was normalized by a
GAPDH-specific RT-PCR.
The expression of IFN- 
mRNA was monitored using
consensus primers amplifying all
IFN-  subtypes. The analysis
was performed with serially five-
fold diluted cDNA samples start-
ing with undiluted material;
spleen derived samples were
fivefold prediluted. 
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mice showed abundant expression of IFN-
 
 
 
2 and 5, whereas
IFN-
 
 
 
4 was found only rarely (Fig. 2 b and c). Thus, dif-
ferent IFN-
 
 
 
 patterns found after VSV infection of MEFs
and mice suggested that in vivo the majority of IFN-
 
 
 
 is
produced by a cell type different from fibroblasts. More-
over, similar IFN-
 
 
 
 patterns found in WT and IFNAR
 
 
 
/
 
 
 
mice indicated a largely feedback-independent production
of early IFN-
 
 
 
 in VSV-infected mice.
 
Early IFNAR-independent and Late IFNAR-dependent
IFN-
 
 
 
 Expression in VSV- and UV-HSV–treated Mice.
 
To
correlate IFN-
 
 
 
 mRNA levels and IFN serum activities,
blood serum of VSV-infected mice was taken and analyzed
in a CPE inhibition assay. As early as 4 h after VSV infec-
tion IFN activity was found in the serum of both WT and
IFNAR
 
 
 
/
 
 
 
 animals. Specific inhibition of IFN-
 
 
 
 and/or
IFN-
 
 
 
 by neutralizing mAbs in the CPE inhibition assay
revealed a major contribution of IFN-
 
 
 
 to the serum IFN
activity, irrespective of whether IFNAR signaling was
functional or not. Serum IFN titers of WT animals in-
creased more rapidly than IFNAR
 
 
 
/
 
 
 
 mice eventually
leading to 
 
 
 
30-fold higher IFN titers in WT animals than
in IFNAR
 
 
 
/
 
 
 
 mice (Fig. 3 a).
Since VSV replication is not controlled in IFNAR-defi-
cient mice, a highly elevated virus load and increased cell
death could have interfered with cytokine production in
IFNAR
 
 
 
/
 
 
 
 mice. Thus, we next analyzed type I IFN re-
sponses after stimulation with nonreplicating virus. Since
UV-inactivated VSV does not induce type I IFN responses
(data not shown), mice were injected with UV-inactivated
HSV. 2 h after the treatment, WT and IFNAR
 
 
 
/
 
 
 
 mice
showed similar peak IFN activity with 
 
 
 
50 and 35% IFN-
 
 
 
contribution, respectively. While the IFN response was
short-lived in IFNAR
 
 
 
/
 
 
 
 mice, IFN titers in WT mice
were sustained for several hours, and a switch to a more
pronounced IFN-
 
 
 
 expression was found (Fig. 3 c). To
verify the induction of early IFN-
 
 
 
 in the absence of
IFNAR-feedback signaling, mice deficient of the IFNAR
or IFN-
 
 
 
 were intercrossed and IFNAR
 
 
 
/
 
 
 
 IFN-
 
 
 
 
 
/
 
 
 
double-knockout mice and IFNAR
 
 
 
/
 
 
 
 IFN-
 
 
 
 
 
/
 
 
 
 litter-
mates were stimulated with UV-HSV. Even in the absence
of IFN-
 
 
 
 initial IFN-
 
 
 
 titers showed the same magnitude
in receptor deficient and competent mice. At later time
points IFN-
 
 
 
 production was sustained and further en-
hanced in IFN receptor competent mice as compared with
IFNAR
 
 
 
/
 
 
 
 mice (Fig. 4). Thus, upon treatment with live
VSV- or UV-inactivated HSV early IFNAR-independent
IFN-
 
 
 
 production is observed. Yet, at later time points
IFNAR-feedback signaling is critical to sustain the produc-
tion of IFN-
 
 
 
.
 
Early IFN-
 
 
 
 Production in the Absence of IRF-7 Induc-
tion.
 
The transcription factor IRF-7 has been shown to
be upregulated upon IFNAR triggering (12, 13) and was
proposed to be critically required for the expression of
IFN-
 
 
 
 subtype genes (12, 35). Therefore, we asked
whether early IFNAR-independent IFN-  was produced
in the absence of IRF-7 induction. The RT-PCR analy-
sis of IRF-7 mRNA levels in VSV-infected WT and
IFNAR /  mice revealed a prompt IRF-7 upregulation
only in WT mice but not in IFNAR-deficient mice (Fig.
5). These experiments indicated that in VSV-infected mice
early IFN-  was induced in the absence of detectable IRF-7
upregulation. At later time points IFNAR-independent
IRF-7 upregulation was observed (data not shown) which,
however, did not suffice to promote a sustained production
of IFN-  in IFNAR /  mice.
Poly(I:C) Treatment of Mice Induces Late IFN-  Produc-
tion. To further study the role of feedback signaling with
a nonreplicating type I IFN inducer, mice were treated
with poly(I:C). Sera of poly(I:C)–treated WT and IFN-
AR /  mice displayed early peak IFN activity, followed by
a rapid decline in the case of IFNAR /  mice. In WT
mice IFN activity was sustained at a high level for  20 h.
Neutralization of IFN-  and/or IFN-  revealed an abun-
dant contribution of IFN-  to early type I IFN activity in
both WT and IFNAR /  mice. At later time points, strong
IFN-  production was observed in WT but not in IFNAR-
deficient mice (Fig. 3 b).
Preferential production of IFN-  after poly(I:C) treat-
ment, while mainly IFN-  is produced after virus stimula-
tion, indicates that different cell types may be involved in the
Figure 2. Differential IFN-  expression profiles of VSV infected MEFs
and mice. PCR products of the IFN-  expression analysis 6 h after VSV
infection of (a) WT MEFs, (b) spleen of WT mice, or (c) spleen of
IFNAR /  mice were subcloned and DNA sequence of 13, 35, and 25
single clones was analyzed, respectively. IFN-  sequences were classified
according to EMBL database entries. The sequence termed IFN- 10
corresponds to the IFN-    sequence available on the EMBL database
(GenBank/EMBL/DDBJ accession no. L38698).511 Barchet et al.
production of poly(I:C)– versus virus-induced type I IFN.
Moreover, these results further support the hypothesis that
the sustained production of IFN-  is IFNAR dependent.
VSV Infection but not Poly(I:C) Treatment Stimulates High-
Level Type I IFN Production in Cells Located in the Marginal
Zone of the Spleen. To localize IPCs, mice were infected
with VSV and 9 h later, spleens were analyzed immunohis-
tochemically with type I IFN-specific antibodies. Consecu-
tive sections were stained with polyclonal antibody di-
rected against type I IFN or with an IFN- –specific mAb.
While staining with the polyclonal serum appeared more
sensitive and decorated a structure surrounding follicles,
i.e., the marginal zone, stainings with mAb revealed dis-
tinct type I IPCs scattered in groups within the marginal
zone (Fig. 6 a and b). After treatment with VSV or UV-
HSV, spleens of WT and IFNAR /  mice showed similar
marginal zone stainings with polyclonal antibody, albeit
staining of spleens from IFNAR-deficient mice was some-
what weaker (Fig. 6 c). Despite comparable IFN levels in
the serum, no specific type I IFN staining was detected in
the marginal zone of poly(I:C)–treated mice (Fig. 6 c).
Thus, after injection of virus particles, irrespective of
whether they are replicative or not, type I IFN production
is localized to the marginal zone. The soluble inducer
poly(I:C) did not induce high enough type I IFN produc-
Figure 3. Type I IFN activity in the serum of
mice treated with VSV, poly(I:C), or UV-HSV.
WT mice (black circles) and IFNAR /  (white tri-
angles) mice were intravenously stimulated with
(a) 2   108 PFU VSV, (b) 100  g poly(I:C), or (c)
2   107 PFU UV-HSV. Mice were bled at the in-
dicated time points and serum IFN titers were de-
termined in a CPE protection assay. A log2 of 5
corresponds to 1,000 IU of IFN- . The contribu-
tion of IFN-  or IFN-  to the total IFN activity
was determined by specific inhibition with mAbs.
Figure 4. IFN-  is produced in mice deficient of IFN-  and IFNAR.
IFN- –deficient mice (black diamonds) and double-deficient mice lack-
ing IFN-  and IFNAR (white diamonds) were intravenously injected
with 2   107 PFU UV-HSV. Sera were taken at indicated time points
and analyzed in a CPE protection assay. Mean IFN activity of three mice
per time point is indicated. Results are shown of one out of two indepen-
dent experiments. Note that the indicated IFN serum activities exclusively
derived form IFN-  because the analyzed mice were IFN-  deficient.512 Feedback Regulation of Type I Interferon Production In Vivo
tion in the spleen to be detected by immunohistology.
Probably under these conditions type I IFN is produced at
a low level by numerous cell types and in various tissues.
In situ hybridization of spleen sections of untreated mice,
with an IRF-7 probe, did not reveal evidence for constitu-
tive IRF-7 expression, neither in few marginal zone cells
nor anywhere else in the spleen (data not shown). After
VSV infection of WT mice a strong IRF-7 induction was
observed all over the spleen. In contrast, no IRF-7 induc-
tion was detected in spleens of VSV-infected IFNAR / 
mice (Fig. 6 d). Together with the above RT-PCR data
these observations indicate that virus-induced early IFN- 
can be produced independent of IFNAR signaling and
IRF-7 upregulation.
Identification of the Major IPC. The phenotype of the
major IPC in VSV pathophysiology is not known. Since
the marginal zone is a complex tissue containing specialized
macrophages, DCs, endothelial cells, and nonrecirculating
B cells, colocalization studies with markers for marginal
zone cells could not further resolve the nature of mouse
IPCs (data not shown). In analogy to the DC origin of hu-
man and mouse IPCs (25, 26, 29, 30) we aimed for the
analysis of mouse DC subsets. Mice were VSV-infected
and, 9 h later, several CD11c  DC subsets were FACS®-
sorted and analyzed for the IFN-  mRNA content (Fig. 7
a). Surprisingly, only CD11cintCD11b GR-I  DCs (frac-
tion D) were strongly positive for IFN-  mRNA, whereas
neither lymphoid DCs (CD11c CD11b , fraction A),
myeloid DCs (CD11c CD11b , fraction B), CD11cint
CD11b  DCs (fraction E), nor granulocytes (CD11c GR-1 ,
fraction F) showed high IFN-  expression (Fig. 7 b). CD11cint
Figure 5. VSV infected IFNAR /  mice show an early induction of
IFN-  before the onset of IRF-7 expression. Total RNA from spleen of
IFNAR /  or WT mice was isolated 3 h after intravenous infection with
2   108 PFU VSV. RT-PCR was performed as described in Fig. 1.
Figure 6. VSV and UV-HSV injection, but not poly(I:C) stimulation, leads to high-level production of type I IFN by cells located in the marginal
zone of the spleen. (a) WT mice were VSV infected and after 9 h spleens were analyzed immunohistochemically with a polyclonal serum against type I
IFN (pAb, top two panels) or with an IFN- –specific mAb (mAb, bottom two panels). (b) A higher magnification of the marginal zone area of the bottom
right panel in (a) stained with mAb is shown. (c) WT and IFNAR /  mice were VSV, poly (I:C), or UV-HSV injected. After 9 h and 6 h after UV-HSV
stimulation, spleens were analyzed immunohistochemically with a polyclonal serum against type I IFN. Sections in (a–c) were counterstained with he-
malum (blue) to visualize lymph follicles. (d) In situ hybridization of IRF-7 mRNA (blue) was performed on paraffin sections of spleen from WT and
IFNAR /  mice prepared 9 h after VSV infection.513 Barchet et al.
CD11b  DCs (fraction C) showed slightly enhanced IFN- 
mRNA levels (which were at least 125-fold lower than
fraction D), that might be due to contaminating cells of
fraction D. We next asked whether CD11cintCD11b GR-I 
cells are producers of IFN-  independent of IFNAR feed-
back signaling. For this purpose DC subsets were isolated
from VSV-infected IFNAR /  mice. Again only CD11cint
CD11b GR-I  cells showed high-level IFN-  mRNA
(Fig. 7 c). These results indicate that although other DC
subsets are able to produce IFN-  upon in vitro stimula-
tion (28), they do not play a major role in IFN-  produc-
tion after VSV infection in vivo.
Discussion
Here we show that after viral infection of mice not only
IFN-  but also IFN-  is produced immediately and largely
independent of IFNAR feedback signaling. This is in con-
trast to the current model of IFNAR feedback-dependent
expression of IFN- , that was established based on in vitro
data. To reconcile the previous in vitro data with our in
vivo observations, we hypothesized that after viral infection
of mice a cell type different from fibroblasts, i.e., the mu-
rine IPC, produced the majority of type I IFN, and that in
these cells IFN-  expression was regulated differently than
in fibroblasts. Indeed, we found that after in vivo infection
the subset of CD11cint.GR-1  DCs produced IFN-  at
high level, and that early IFN-  production by this cell
type was largely independent of IFNAR feedback.
The positive feedback regulation of IFN-  genes was
first observed in NDV-infected MEFs that lack IFN-  ex-
pression in the absence of a functional IFN signaling cas-
cade (11, 12). One study showed IFNAR-independent
IFN- 4 expression in NDV-infected MEFs (13). Interest-
ingly, IFN- 4 was previously found to dominate IFN- 
responses of NDV-stimulated L929 fibroblasts (36). How-
ever, MEFs infected with VSV (Fig. 1), or vaccinia virus
(37) showed a strictly IFNAR-dependent expression of all
IFN- s. Equally, Sendai virus-infected MEFs from IFN- –
deficient mice were found unable to produce any IFN- ,
unless stimulated by the addition of exogenous IFN-  (14).
In contrast to these in vitro data, we found that VSV-
infected mice mount an early IFNAR-independent IFN- 
response. Furthermore, IFN- –deficient and IFN- /
IFNAR double-deficient mice treated with UV-HSV still
expressed substantial IFN-  levels (Fig. 4). While IFN- 
production in IFN-  /  mice could have been promoted
by priming with natural type I IFN, produced pathogen in-
dependently (38), IFN-  production in IFN- /IFNAR
double-deficient mice indicated that IFNAR triggering
was not a prerequisite for early IFN-  production. IFN- 
levels reached in IFN-  /  were sufficient to control intra-
venous VSV infection (data not shown). In contrast, IFN-
 –deficient mice infected peripherally with vaccinia virus
showed a markedly increased susceptibility to lethal disease
(37): after intranasal infection, IFN-  /  mice showed up
to 105-fold increased virus titers in the lung as compared
Figure 7. In VSV-infected mice CD11cintCD11b GR-1  DCs ex-
press high-level IFN- . (a) Mice were intravenously infected with 2  
108 PFU VSV and 9 h later spleens were removed to prepare single cell
suspensions. MACS®-enriched CD11c  cells were stained with anti-
CD11c-Biot./Str.-APC, anti-CD11b-FITC, and anti-GR-1-PE, and
DC subsets were FACS®-sorted using the indicated gates A–F. Cells
from gate C/D were further subdivided by separating GR-1  (fraction
C) and GR-1  cells (fraction D). Sorted fractions were derived from
spleen of (b) VSV infected or untreated C57BL/6 mice, and of (c) VSV-
infected Sv129 (WT) and IFNAR /  mice. Total RNA of  4–10   104
sorted cells was prepared and analyzed by RT-PCR as described in
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with WT mice, and eventually succumbed to the infection.
Interestingly, in these experiments virus titers in spleen of
WT and IFN-  /  mice were comparably low, indicating
that upon local infection vaccinia virus replication was bet-
ter controlled in the spleen than in the peripherally infected
organ. Thus, it appears that depending on the route of in-
fection virus may activate IPCs or other susceptible cell
types that differ in their requirement of IFNAR feedback
for the IFN-  induction.
Apart from the route of infection also the nature of the
stimulus may determine the cell type(s) involved in type I
IFN production. Our histology data show that poly(I:C)
does not induce marginal zone IPCs to produce high-level
type I IFN, suggesting that the observed IFN titers were
contributed mainly by nonIPCs. It is possible that in anal-
ogy to the human plasmacytoid DCs, mouse IPCs express
TLR-9 but not TLR-3 that is involved in poly(I:C) recog-
nition (19, 21), and thus mouse IPCs are not triggered by
poly(I:C). IFN titers in poly(I:C)–treated mice showed an
early peak of IFN-  expression that only in animals with a
functional receptor feedback was followed by sustained
IFN-  expression. This indicated that similar to in vitro
VSV-infected MEFs, IFN-  expression by nonIPCs in
vivo required IFNAR feedback signaling.
In the current model of positive feedback regulation,
IFNAR-dependent upregulation of the transcription factor
IRF-7 plays a central role. Virus-treated mutant MEFs that
failed to induce IRF-7 also lacked expression of IFN- .
The IFN-  response could be restored by ectopic expres-
sion of IRF-7 (12). In IFNAR-deficient mice, we ob-
served early IFN-  responses in the absence of detectable
IRF-7 upregulation. One possibility is that under these
conditions low constitutive IRF-7 levels suffice to drive
early IFN-  expression. In this context it is worth noting
that in all RT-PCR experiments, unlike other DC subsets,
CD11cintCD11b GR-1  DCs (fraction D) showed some
background IRF-7 expression already in uninfected WT
mice (Fig. 7 b). Alternatively, IPCs might be able to utilize
an IRF-7–independent pathway for IFN-  expression, as
suggested by the recent finding, that ectopic expression of
IRF-5 can substitute for IRF-7 to allow expression of cer-
tain IFN-  genes (39). Ultimately, only the generation and
analysis of IRF-7–deficient mice can define the role of
IRF-7 in the expression of virus-induced IFN-  in vivo.
Our immune histological analysis of VSV-infected mice
revealed that IPCs are predominantly located in the mar-
ginal zone. Similarly, we and others have found the same
IPC distribution in UV-HSV–treated mice (27, 40). The
importance of the marginal zone for pathogen surveillance
was demonstrated by the scavenger function of marginal
zone cells, which can retain microscopically small particles,
including pathogens, from the blood (41). Mice that were
experimentally depleted of macrophages in the marginal
zone (42), and osteopetrotic (op) mutant mice that are
M-CSF deficient and lack the same macrophage popula-
tions, showed an increased sensitivity to pathogen infection
(43). Thus, in order to be stimulated early in the course of
an infection it appears “reasonable” that IPCs are located in
the marginal zone. From histological colocalization studies
it had been concluded that MOMA-1  metallophilic and
ERTR-9  marginal zone macrophages might be involved
in type I IFN production (27). Since we could not observe
a strict correlation of MOMA-1 and ERTR-9 versus IFN-
 /  stainings, and after recent evidence that the human
and mouse IPC are plasmacytoid DCs (25, 26, 29, 30), we
FACS®-sorted several DC subsets from spleen of VSV-
infected mice and analyzed them for IFN-  mRNA ex-
pression. These experiments indicated that the subset of
CD11cintCD11b GR-1  DCs showed high IFN- 
mRNA levels. Interestingly, we did not find increased lev-
els of IFN-  message in myeloid or lymphoid DCs (frac-
tions A and B, respectively) isolated from VSV-infected
mice, as could have been expected form recent in vitro
data (28).
In conclusion, we suggest to extend the current model
of IFNAR feedback dependent expression of IFN-  as fol-
lows. (i) In vivo, local infections may stimulate the produc-
tion of mainly IFN-  by nonIPCs to protect surrounding
tissues in a paracrine fashion. These cells produce IFN- 
IFNAR dependently, i.e., only if sufficient autocrine type I
IFN stimulation is provided. (ii) Systemic infection and
acute viremia that require a generalized antiviral state may
stimulate IPCs to produce IFN-  early and at high-level
independent of IFNAR feedback signaling; however,
IFNAR feedback defines the magnitude and duration of
sustained IFN-  production.
To our knowledge, we present the first set of ex vivo
data defining IPCs in viral pathogenesis. Our results sup-
port the concept that highly specialized DCs, located in the
marginal zone, produce type I IFN upon pathogen contact.
The observation that early IFN-  production of mouse
IPCs is largely independent of IFNAR signaling indicates a
less stringently regulated IFN-  expression in IPCs as com-
pared with other cell types. Further experiments will re-
veal, whether, depending on the tissue tropism and the
stimulation mechanism, different pathogens may activate
discrete cell populations to produce type I IFN, and
whether mouse IPCs do play a role in antigen processing
and presentation. A better understanding of the role of
IPCs in viral pathophysiology can have important diagnos-
tic and therapeutic implications, as exemplified by publica-
tions showing reduced IPC counts in HIV-infected AIDS
patients (44, 45).
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